

Zzoma® Marks Major Adoption and Patient Satisfaction Milestones; Eyes Philadelphia Conference Participation

PHILADELPHIA, PA, UNITED STATES, March 20, 2024 /EINPresswire.com/ -- Sleep Specialists, LLC, makers of Zzoma®, an innovative positional therapy for mild to moderate obstructive sleep apnea (OSA), today announced substantial growth, positive internal survey results, and their upcoming participation in the Philadelphia Sleep Conference.

The company has surpassed its recent milestone of 1,000 prescribing physicians and 800 sleep clinics. Sleep Specialists now proudly partners with over 1,700 physicians and has been adopted by more than 1,300 sleep centers across the country. This rapid expansion underscores the demand for effective, patient-centered alternatives to CPAP.



Adding to this success, Sleep Specialists conducted an internal sample of Zzoma users (N=100), revealing overwhelmingly positive results:

- ☐ 74.7% of users find Zzoma easy to use.
- ☐ 78.7% of users report improved quality of life.
- ☐ 89.4% report waking up feeling better.
- ☐ 88.1% report improved sleep quality.

These results confirm Zzoma's impact on sleep health and its position as a reliable and

comfortable solution for those with mild to moderate OSA.

"We're thrilled to see Zzoma's widespread adoption alongside such positive patient feedback," said Michael J. Markus, PhD, Executive Director at Sleep Specialists, LLC. "These results confirm Zzoma's impact on sleep health and its position as a reliable and comfortable solution for those with mild to moderate OSA."

000 00000000 00 00000:

- 🛮 🖺 🖺 🖺 🖺 🖺 🖺 🖺 🖺 🖺 🖺 🖺 🖰 Eliable solution for their patients.
- □ □□□□□□□ □□□□□□□: Zzoma's comfortable design leads to improved compliance and better sleep outcomes.
- 🛘 🖺 🖺 🖺 🖺 🖺 🖺 🖺 🖺 🖺 🖺 🖽 Expanding partnerships and investments ensure even wider accessibility to Zzoma in the United States and globally.

Sleep Specialists, LLC will be in attendance at the 12th annual Philadelphia Sleep Conference on Friday, March 22nd, 2024. Visit our booth or schedule a virtual visit to learn more about Zzoma and our dedication to transforming OSA treatment. This conference welcomes all sleep medicine professionals.

00000 00000 00000000000, 000

Sleep Specialists, LLC is a rapidly growing medical device and services company dedicated to developing innovative solutions for sleep-related disorders. Their flagship product, Zzoma, is a clinically proven, <u>FDA-cleared positional therapy device</u> for Obstructive Sleep Apnea (OSA). Sleep Specialists is experiencing substantial momentum, marked by:

- ☐ Strategic partnership with First Nation, expanding access to Zzoma in government hospitals.
- ☐ Investment in US manufacturing, ensuring product availability and domestic production.
- ☐ International expansion, reaching new markets with their effective solution.
- ☐ Over 1,700 physicians and 1,300 sleep centers prescribing Zzoma, demonstrating growing recognition of its value in treating OSA patients.

Additional Conference Information and Continuing Education Credits:

- 🛘 🖺 🖺 🖺 🖺 🖺 🖺 🖺 🖰 Physicians (MD, NP, PA, DO), Dentists, Psychologists (including those from New York), Registered Nurses, Sleep Technologists, Respiratory Therapists
- □ □□□ □□□□□□□ (□□□□□□□□□□□□□□□□□□□): 6 for in-person attendance.
- 0 0000 000000 (00000 00000000000): 10 for in-person or live streaming.
- 0 0000 000000 (000000000 000000000): 10 for in-person or live streaming.

ZZOMA
Sleep Specialist, LLC
+1 877-799-9662
info@zzomaosa.com
Visit us on social media:
Facebook
Twitter
LinkedIn
Instagram

This press release can be viewed online at: https://www.einpresswire.com/article/697362777

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2024 Newsmatics Inc. All Right Reserved.